SAN FRANCISCO, June 11, 2019 /PRNewswire/
-- DarioHealth Corp. (NASDAQ: DRIO), a leading global
Digital Therapeutics (DTx) company with connected devices, mobile
software and large data solutions presented two studies reporting
new real-world results at the American Diabetes Association's (ADA)
79th Scientific Sessions in San Francisco, California.
Yifat Hershcovitz PhD. performed the two studies with
Sharon Dar and Eitan Feniger of DarioHealth. The studies
provide additional insights on how the use of Dario's mobile
applications, within a complete digital therapeutics solution, may
promote behavioral modifications and enhanced individual engagement
with diabetes management. The study demonstrates how this
behavioral change may improve glycemic outcomes sustained for a
long period of time.
The studies present a retrospective data evaluation reviewing
hundreds of Type 2 Diabetes (T2D) active Dario mobile app
users.
More specifically, they highlight the following results:
- T2D Users of a Digital Diabetes Management System
Experienced an Increase of In-Range Glucose Levels Linked to App
Engagement. For 4,917 T2D users measuring more than 15 times
per month, the average of % in-range readings (70-140 mg/dL) was
increased in correlation to app engagement (occurrences of tagging
meals, carbs, physical activity). For 833 T2D highly engaged
(≥7 times per week) population the ratio of % in-range readings was
increased by 10% and sustained for 6 months.
- Reduction of Blood Glucose Average Under 140mg/dL in People
with T2D Using a Digital Diabetes Management. For 1,248
Dario active users with T2D, measuring more than 2 times per day on
average for 6 months in a row, reduction of their blood glucose
average (BG avg) was observed within the 6-month period. Of that
group, 31% (387 users) achieved BG avg of <140 mg/dL
(eA1C<6.5) after 3 months, showing a 19% reduction on average
from baseline. Subgroup analyses of 568 non-insulin
users revealed that 40% (226 users) achieved a BG avg <140 mg/dL
after 3 months and sustained it for 6 months.
Furthermore, the research team revaluated extended real-world
data for analysis published originally in ADA 2018 titled 'Type 2
Diabetes Users of a Digital Diabetes Management System Experience a
Shift from Greater than 180 mg/dL to Normal Glucose Levels with
Sustainable Results' for 17,156 active users. The analysis
combining 2017 and 2018 data which total in 38,838 T2D active users
and more than 3 million measurements showing comparable results to
the 11.3% increase in the ratio of normal blood glucose range
readings (80-120 mg/dL) and 19.3% reduction in average high blood
glucose events (180-400mg/dL).
Olivier Jarry, President and
Chief Commercial Officer of DarioHealth, commented, "It is a
great honor to present these studies at the ADA's Scientific
Sessions. Leveraging a methodological approach, our
researchers could demonstrate positive gains in outcomes. Based on
the studies, we believe that better engagement clearly leads to
better health and improved clinical outcomes. Such engagement stems
from years of experience in developing and refining a unique user
experience that is encouraging frequent and meaningful interaction
with the mobile application."
Erez Raphael, Chief Executive
Officer of DarioHealth, commented, "At DarioHealth, we are
continuing the journey in setting the standards in the Digital
Therapeutics industry to provide self-management excellence. These
studies, involving large real-world populations, create further
evidence of the benefits that our platform provides to our users.
We are utilizing real-world data and redefining the way we think
about chronic conditions management."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we developed a novel approach that empowers
individuals to adjust their lifestyle in a personalized way. Our
Cross Functional Team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Already one of the
highest rated Diabetes solutions, its user-centric approach is
loved by tens of thousands of consumers around the globe.
DarioHealth is rapidly moving into new chronic conditions and
geographic markets.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that it believes that better engagement clearly leads to better
health and improved clinical outcomes and that the studies create
further evidence of the benefits that Dario's platform provides to
its users, it is using forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
347-767-4220
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-reports-improvement-in-glycemic-outcomes-with-key-diabetes-findings-at-the-american-diabetes-associations-79th-scientific-sessions-300865248.html
SOURCE DarioHealth Corp.